MDXH mdxhealth
Price Chart
Executive Summary
Mdxhealth highlighted new data from the Oxford-led ProMPT study showing its GPS mdx genomic test can predict favorable outcomes in prostate cancer patients across multiple treatment settings, supporting its use in guiding treatment de-escalation and avoiding overtreatment. The results were presented at the EAU 2026 conference and represent a key milestone in the ongoing GPS-ProtecT study collaboration with Oxford.
Actionable Insight
Traders should monitor for potential coverage expansions by payers and future data readouts from the larger ProtecT trial, which could serve as a catalyst for broader commercial adoption and valuation re-rating.
Key Facts
- New data from the GPS-ProMPT study (n=409) show GPS mdx test effectively stratifies risk of treatment failure in localized prostate cancer across active surveillance, surgery, and radiotherapy.
- Six-year freedom-from-failure was 92% in active surveillance patients and up to 100% in surgery/radiotherapy patients with favorable GPS scores, even among clinically high-risk groups.
- Results presented at EAU 2026 by Professor Freddie Hamdy, University of Oxford, a leading prostate cancer researcher.
- Part of broader GPS-ProtecT study collaboration with Oxford, leveraging long-term data from the landmark UK ProtecT trial (n>1,500).
- GPS mdx is a 17-gene assay that assesses tumor biology to guide personalized treatment decisions between active surveillance and definitive therapy.
Financial Impact
Potential for increased adoption and reimbursement as clinical validation strengthens; no direct financial figures reported.
Risk Factors
- No immediate revenue impact; clinical adoption and reimbursement may lag despite strong data.
- Forward-looking statements about future benefits are subject to regulatory, payer, and market acceptance risks.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3256649 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Apr 30, 2026
6w ago
|
6-K
| $2.04 $0.7600 | ▼ −62.75% | ▼ −67.97% | $0.5420 (−73.43%) |
|
Apr 13, 2026
8w ago
|
3
| $2.27 $1.99 | ▼ −12.33% | ▼ −18.63% | $0.5420 (−76.12%) |
|
Apr 11, 2026
9w ago
|
3
| $2.14 $1.99 | ▼ −7.01% | ▼ −14.74% | $0.5420 (−74.67%) |
|
Mar 16, 2026
12w ago
|
Press Release
| $3.36 $2.31 | ▼ −31.25% | ▼ −35.55% | $0.5420 (−83.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access